An antibody is provided that inhibits infection of cells with a norovirus. The antibody is a nanoantibody comprising a polypeptide described in (a), (b), or (c), and inhibiting infection of intestinal cells with HuNoV GII.4: (a) a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 13; (b) a polypeptide consisting of an amino acid sequence comprising a substitution, deletion, insertion and/or addition of one or several amino acids with respect to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 13; and (c) a polypeptide consisting of an amino acid sequence having a sequence identity of 80% or more to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 13.

Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.

The present disclosure is directed to antibodies binding to human respiratory syncytial virus F protein, including both neutralizing and non-neutralizing antibodies, and methods for use thereof.

The invention relates to methods for the preparation of a pharmaceutical-vesicle formulation comprising steps of: preparing and processing vesicle components and a pharmaceutical agent to entrap the pharmaceutical agent in the vesicle and form a pharmaceutical-vesicle formulation, wherein the pharmaceutical-vesicle formulation is reconstituted in a known quantity of the pharmaceutical agent dissolved in a pharmaceutically-acceptable carrier to provide a biphasic pharmaceutical-vesicle formulation. The invention also relates to the associated pharmaceutical-vesicle formulations, pharmaceutical kits and uses as a medicament, in particular for the prevention or treatment of infection by bacteria such as Burkholderia pseudomallei and Francisella tularensis, and viruses such as Venezuelan Equine Encephalitis Virus (VEEV).

The present invention addresses the issue of providing a norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration which vaccine can readily immunize the target cells, an associated product of a molecular needle serving as an active ingredient of the vaccine, and a production method for the associated product. The invention provides a norovirus component vaccine containing, as an active ingredient, an associated product including a hexamer formed through bonding of two molecules of a trimer of a molecular needle represented by the following formula (1). W-L.sub.1-X.sub.n—Y (1) [wherein W represents an amino acid sequence of P domain of the capsid protein of norovirus as an immunogen; L.sub.1 represents a first linker sequence having 0 to 100 amino acids; X represents an amino acid sequence represented by SEQ ID NO: 1; Y represents an amino acid sequence of a cell introduction domain; n is an integer of 1 to 3].

The present disclosure is directed to antibodies binding to and neutralizing hantavirus and methods for use thereof.

The present disclosure is directed to antibodies binding to and neutralizing hantavirus and methods for use thereof.

The presently-disclosed subject matter relates to crosslinkers, compositions, and methods for trapping a target of interest on a substrate of interest. The methods may be used to inhibit and treat pathogen infection and provide contraception. The methods may be used to trap or separate particles and other substances. The subject matter further relates to methods of identifying and preparing optimal crosslinkers and methods for manipulating targets of interest.

The present disclosure discloses a nano antibody for neutralizing a toxicity of SARS-CoV-2 and preparation method thereof. The nano antibody comprises a complementarity determining region CDR comprising a CDR1, a CDR2 and a CDR3; an amino acid sequence of the CDR1 is selected from at least one of amino acid sequences shown in SEQ ID NO.1 and SEQ ID NO.2; an amino acid sequence of the CDR2 is selected from at least one of amino acid sequences shown in SEQ ID NO.3, SEQ ID NO.4, and SEQ ID NO.5; and an amino acid sequence of the CDR3 is selected from at least one of amino acid sequences shown in any one of SEQ ID NO.6 to SEQ ID NO.9. The nano antibody for neutralizing the toxicity of SARS-CoV-2 has the advantages of a small molecular weight, a high affinity with the SARS-CoV-2, a low production cost, and the like.

The present disclosure discloses a nano antibody for neutralizing a toxicity of SARS-CoV-2 and preparation method thereof. The nano antibody comprises a complementarity determining region CDR comprising a CDR1, a CDR2 and a CDR3; an amino acid sequence of the CDR1 is selected from at least one of amino acid sequences shown in SEQ ID NO.1 and SEQ ID NO.2; an amino acid sequence of the CDR2 is selected from at least one of amino acid sequences shown in SEQ ID NO.3, SEQ ID NO.4, and SEQ ID NO.5; and an amino acid sequence of the CDR3 is selected from at least one of amino acid sequences shown in any one of SEQ ID NO.6 to SEQ ID NO.9. The nano antibody for neutralizing the toxicity of SARS-CoV-2 has the advantages of a small molecular weight, a high affinity with the SARS-CoV-2, a low production cost, and the like.